Abstract
The gut microbiota, including pathogenic microorganisms and probiotics, has been involved in tumor initiation and progression by regulating the components of intestinal flora. Canmei formula (CMF), a traditional Chinese medicine, chronicled in the Chuang Yang Jing Yan Quan Shu, has been clinically used as an adjuvant therapy to treat patients with colorectal carcinoma (CRC) in China. In this study, we investigate the treatment effect of CMF in the azoxymethane (AOM) and dextran sodium sulfate (DSS) induced and high-fat diet augmented colitis-associated colorectal cancer in vivo, and explore its mechanism of action. We found that CMF treatment relieved the inflammation and alteration of the gut microbiota and significantly inhibited the development of intestinal adenoma. Linear discriminant analysis showed that the flora diversity in the normal mice, model mice and CMF treatment mice was different. At the family level, the relative abundance of Desulfovibrionaceae decreased in CMF groups. The relative abundance of Desulfovibrionaceae were lower in the CMF groups than in model group, whereas Rikenellaceae and Alistipes were increased. Altogether our results indicate that CMF treatment ameliorate colitis-associated colorectal carcinogenesis by modulating the composition of the gut microbiota in vivo.
Highlights
Colorectal carcinoma (CRC) is the second leading cause of cancer-related death worldwide [1]
To exclude the possibility of manufacturing problems relating to procession, extraction, handling, and storage, two batches of Canmei formula (CMF) were evaluated by HPLC
Wei et al showed that JianPi JieDu decoction (JPJD) is able to inhibit tumorigenesis, metastasis, as well as angiogenesis of tumors through the mTOR/HIF-1α/VEGF pathway [18]
Summary
Colorectal carcinoma (CRC) is the second leading cause of cancer-related death worldwide [1]. Colorectal adenoma (CRA) refers to any lesion that originates from the surface of colorectal mucosa and protrudes into the intestinal cavity. It is a precancerous lesion of CRC and has the characteristics of high recurrence and high incidence of cancerous change [3]. Microscopic removal is currently the main treatment for CRA, which can effectively reduce the incidence of CRC and reduce mortality. Celecoxib, and cyclooxygenase-2 inhibitors are used clinically to treat inflammatory bowel disease, but the efficacy is limited according to the large sample clinical data [5].
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have